Houttuynia Safety: Family Questions, Dose and Unknowns

Kidney tissue, the organ aristolochic acid harms
Kidney tissue, the organ aristolochic acid harms
Dried houttuynia as sold in herbal markets
Dried houttuynia as sold in herbal markets
Powdered herb checked under the microscope
Powdered herb checked under the microscope

A reader who has heard of aristolochic acid and then reads that Houttuynia cordata sits in the same botanical order as the birthworts is entitled to be worried, and to be given a straight answer rather than either a dismissal or a scare. Aristolochic acid is one of the genuinely dangerous compounds in the herbal world: a potent nephrotoxin and a human carcinogen, responsible for an epidemic of kidney failure and urothelial cancer. If fish mint carried it, that would be the only thing worth saying about the plant.

It does not. Houttuynia cordata is not an established aristolochic-acid-containing plant, analytical testing of correctly identified material has not found aristolochic acids in it, and presenting it as if it did would be wrong. Getting that wrong in the alarmist direction is as much an error as getting it wrong in the reassuring one — manufacturing a hazard is not caution.

What survives the question is narrower and more interesting than the question itself, and it is worth the page: what order-level relatedness is and is not worth as evidence; why the compounds Houttuynia actually contains are chemically downstream of the dangerous ones rather than equivalent to them; why the real historical hazard in this corner of herbal medicine has been substitution rather than the correct species; and why a certificate of analysis showing a marker compound tells you nothing about which plant is in the jar.

Table of Contents

  1. Piperales: What Order-Level Relatedness Is Worth
  2. Aristolochic Acids and Aristolactams Are Not the Same Compound
  3. What Analytical Testing Found
  4. The Real Historical Hazard Was Substitution
  5. A Marker Assay Is a Potency Check, Not an Identity Check
  6. What Remains Genuinely Open
  7. Other Safety Points, Handled Briefly
  8. Hazards Houttuynia Does Not Have
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Piperales: What Order-Level Relatedness Is Worth

The botanical fact is correct, and worth stating precisely. Houttuynia cordata belongs to the Saururaceae, the lizard's-tail family — a small group of a few genera. Saururaceae sits in the order Piperales. So does the Aristolochiaceae, the birthwort family, which is where aristolochic acid comes from. Same order, different families.

The clean way to see what that is worth is to look at the third major family in the same order: the Piperaceae. Black pepper is a Piperaceae. So is kava. Nobody has ever suggested testing black pepper for aristolochic acid, and there is no reason to — because taxonomic order is far too coarse a unit to predict secondary chemistry.

Some scale for that. An order groups families that shared an ancestor tens of millions of years ago. Within one order you routinely find families whose useful chemistry has nothing in common. The relevant secondary-metabolite pathways are typically distributed at the level of family, genus, or even a subset of species within a genus — which is why Artemisia annua makes artemisinin and its close relatives largely do not.

The same reasoning applies inside the Aristolochiaceae in the direction of caution, and that is the more useful half:

So the honest summary of the taxonomy point: the family is the informative unit here, and the family is clean. Order membership prompted a reasonable question, the question was answered analytically, and the answer did not depend on the taxonomy at all. That is how the process is meant to work — relatedness generates a hypothesis, chemistry tests it.

Aristolochic Acids and Aristolactams Are Not the Same Compound

Houttuynia does contain compounds in a related structural class: aristolactams. Which ones depends on the study. A 2025 study names aristolactam I and aristolactam BII as the predominant ones. Two 2022 market surveys found aristolactam AII in their samples, and the larger one, of 75 batches, also measured aristolactams FI and BII; the 22-sample survey did not detect aristolactam I in any sample. This is the true premise underneath the worry, and it needs to be handled chemically rather than by name similarity — the names are confusingly close in English and closer still in Chinese, which is part of why the anxiety spread.

The difference that matters is the mechanism of harm:

  1. Aristolochic acids carry a nitro group. They are nitrophenanthrene carboxylic acids, and their toxicity depends on that nitro group being reduced in the body. Nitroreduction generates a reactive intermediate — a nitrenium ion — which binds covalently to DNA, forming adducts on adenine. Those adducts produce the characteristic A-to-T mutation signature found in the tumours of exposed people, including in the TP53 gene.
  2. Aristolactams do not carry that nitro group. Chemically they sit downstream: aristolactam I is a known metabolite of aristolochic acid I, formed after the reactive step has happened. It is an end product of the activation pathway, not a precursor that can enter it.

That distinction is the heart of the matter. A compound whose danger comes from being metabolically activated is a different proposition from a compound that is already the deactivated end product. It does not make aristolactams inert — aristolactam I has been reported as toxic to isolated human kidney cells in culture, and in one comparison more so than aristolochic acid I itself (in the 2025 study below, the concentration that cut the survival of cultured human kidney cells by half was 2.76 µM for aristolactam I against 79.85 µM for aristolochic acid I, so a much smaller amount of aristolactam I did the same damage in the dish) — but cell-culture toxicity is not what happens in a body, which is the next section's point in miniature.

A 2025 study in Food Research International fed aristolactam I, aristolactam BII and a whole aristolactam fraction from Houttuynia to mice, using aristolochic acid I as a positive control. The positive control did what it always does — clear kidney injury. The aristolactams produced only modest changes in body weight, serum kidney markers and urinary injury biomarkers. The explanation offered is pharmacokinetic rather than a claim that the compounds are harmless: oral bioavailability of aristolactam I was reported at roughly half, against essentially complete absorption for aristolochic acid I (52.71 percent for aristolactam I and 39.60 percent for aristolactam BII, against 99.83 percent for aristolochic acid I); it was metabolised into less toxic derivatives; and no unchanged aristolactam appeared in urine. Poor absorption and rapid metabolism kept it away from the kidney.

Two caveats belong with that, because a single mouse study is a single mouse study. It is one experiment, in one species, at whatever doses and duration it used — this page does not quote a milligram-per-kilogram figure it cannot verify — and rodent pharmacokinetics do not automatically transfer to humans. The finding is genuinely reassuring in direction. It is not a human safety demonstration, and it is the only animal study of its kind on these specific compounds from this plant.

What Analytical Testing Found

The direct question — does the plant make aristolochic acids? — has been answered directly, which is the best possible outcome for a question of this kind.

A Hong Kong group used liquid chromatography with tandem mass spectrometry, the reference technique for this analysis, on twenty samples of fresh and sun-dried Houttuynia cordata collected from different Chinese cities, with detection limits in the low nanograms-per-gram range. Aristolochic acids I and II were absent or below the limit of detection in every sample. The authors' conclusion was that eating Houttuynia is unlikely to cause aristolochic acid nephropathy, because the plant is not making the carcinogens. The work was published in the Journal of Mass Spectrometry.

Three things about that study are worth a reader's attention, and one is a limitation:

Two later laboratory surveys, both published in 2022, widen that sample. One tested 22 samples collected from 22 different regions of China and detected none of aristolochic acid I, aristolochic acid II or aristolactam I in any of them; aristolactam AII, which has not been reported to damage genes (genotoxicity), was found in every sample. The other, from China's National Institutes for Food and Drug Control, tested 75 batches of the dried herb from different origins and found no aristolochic acids at a detection limit of 4 ng/mL or lower.

The Real Historical Hazard Was Substitution

Every documented episode of aristolochic acid poisoning through herbal medicine involved a plant that was not what the label said, or a plant whose aristolochic acid content was never in question. Reading those episodes as "Chinese herbs cause kidney failure" gets the causal structure wrong, and reading them as "it was only an adulteration, so the herb is fine" gets it wrong in the other direction.

The defining case is Belgian. In the early 1990s a cluster of young women developed rapidly progressive interstitial renal fibrosis after attending a weight-loss clinic; the case series appeared in The Lancet in 1993. That paper's own chemical analysis of some brands of the herbs had not found aristolochic acid; its identification in the Chinese herbs was reported in a 1994 Lancet letter. The preparation contained a Chinese herb, and the herb supplied was Aristolochia fangchi rather than the intended Stephania tetrandra. The two share a similar Chinese name — fang ji — and were confused in the supply chain. Many of the affected women went on to end-stage renal failure, and a follow-up study reported in the New England Journal of Medicine in 2000 found urothelial carcinoma in a substantial proportion of those who had their urinary tracts removed: 18 of the 39 patients who agreed to preventive removal of their own kidneys and ureters (46 percent), with total doses of more than 200 g of the Aristolochia herb linked to a higher risk. Separately, work published in PNAS in 2007 linked aristolochic acid to Balkan endemic nephropathy, where the exposure route appears to have been Aristolochia clematitis seed contaminating wheat, and a 2012 PNAS study connected aristolochic acid exposure to the very high rate of upper urinary tract cancer in Taiwan. The International Agency for Research on Cancer classifies aristolochic acid mixtures and plants containing them as carcinogenic to humans.

Now the part that is easy to skip. Attributing that harm to substitution clears the plant, not the bottle:

  1. The substitution happened because names collide. Fang ji in Belgium; more broadly, similar herb names, similar dried appearances and long informal supply chains. Those conditions have not disappeared.
  2. If you cannot tell which plant you bought, the hazard is worse, not better. "It was a different species" is only reassuring if you can verify which species you have. For a dried, powdered, encapsulated product, most buyers cannot.
  3. Most implicated products were never analysed. The reattribution to Aristolochia rests on the batches that were investigated. That is normal and it is also a limit on how much the reattribution proves.
  4. The consequence points at product form, not at the species. Fresh fish mint bought as a vegetable, with roots and soil attached, in a Vietnamese grocery, is a plant you can see, smell and identify. An imported capsule labelled "Houttuynia extract" is a powder you cannot. The risk difference between those two purchases has nothing to do with botany.

A Marker Assay Is a Potency Check, Not an Identity Check

Supplement labels answer the verification problem with a certificate of analysis: "standardised to X% quercitrin," "assayed for total flavonoids." That is worth less than it looks, and the reason is worth understanding once, because it applies to every herbal product a reader will ever buy.

An assay for a marker compound measures how much of that compound is present. It does not establish which plant the compound came from. Quercitrin, rutin, hyperoside and chlorogenic acid — the compounds a Houttuynia product would plausibly be standardised to — are distributed across enormous swathes of the plant kingdom. A product could hit its quercitrin specification using material that is largely something else entirely, and the certificate would pass.

What does establish identity:

The practical upshot is unglamorous and reliable: the vegetable can be identified by eye; the capsule cannot. Fresh bunches sold as food in a Vietnamese or Chinese grocery, or dried dokudami-cha from a Japanese supermarket, are products whose identity a buyer can verify with their own eyes and nose. That is a better authentication than most certificates of analysis, and it costs less.

What Remains Genuinely Open

Naming the unknowns as findings, rather than leaving them to be inferred:

  1. No long-term human study of concentrated extract exists. Not a negative result — an absent one. Nobody has followed people taking a standardised Houttuynia extract daily for years with renal function and urinary-tract outcomes. That study has not failed; it has not been done.
  2. No human pharmacokinetics for the aristolactams. The reassuring bioavailability argument comes from one mouse study. The corresponding human numbers do not exist.
  3. No aristolactam content figure for the plant appears here. Published values would depend on plant part, origin, season, drying and analytical method, and this page could not verify a representative figure. A confident milligrams-per-gram number would be a guess, and it would be the number readers quoted afterwards.
  4. No established safe or unsafe dose, for any form. There is no therapeutic dose because there is no proven therapeutic effect, and there is no toxic threshold because no dose-finding toxicology has been done in humans.
  5. Only rat data on a concentrated extract. A 2021 study gave rats a concentrated 95% ethanol extract by mouth for 28 days. It found no significant harmful effect at 250 mg/kg a day, but five rats died in the 500 and 1,000 mg/kg-a-day groups and showed liver and kidney toxicity, and male rats were more affected than females. This is animal data on a concentrated extract, not on the vegetable or the tea.
  6. No data in pregnancy or lactation beyond customary practice. Culinary amounts have a long record of use including by pregnant women in Vietnam and Japan, with no signal of harm. That is an observation, not a study. For medicinal doses, extracts and capsules there is no safety data in pregnancy, and the one toxicity study of a concentrated extract, in rats, found liver and kidney damage at high doses.
  7. No interaction studies. None, in either direction, with any prescription medicine. "No known interactions" for this plant means nobody has looked.
  8. No paediatric safety work. Vietnamese and Japanese practice includes giving the juice and the tea to children, which is a real observation about tolerability at those amounts, and there is no formal study.

These gaps matter most for people with chronic kidney disease or a history of acute kidney injury, anyone with a urothelial cancer history, transplant recipients, and anyone pregnant. For those readers the distinction is specific and narrow: the food and the ordinary tea are not the issue; concentrated extract capsules are the form with no human safety data behind them, and a concentrated extract tested in rats damaged the liver and kidney at high doses.

Other Safety Points, Handled Briefly

Hazards Houttuynia Does Not Have

Readers arriving from other herb pages carry specific worries with them, and clearing the ones that do not apply is as much a part of an accurate safety page as listing the ones that do. On current evidence, Houttuynia cordata is not associated with:

Key Research Papers

Each named paper links to its PubMed record. Where the page refers to a body of work rather than one paper, a topic search is linked instead.

  1. Chan CK, Pan G, Chan W. Analysis of aristolochic acids in Houttuynia cordata by liquid chromatography-tandem mass spectrometry. J Mass Spectrom. 2021;56(4):e4652. PubMed PMID: 32975339 — aristolochic acids I and II absent or below a detection limit as low as 2 ng/g across twenty fresh and sun-dried samples. The single most important paper on this page.
  2. Xue S, Wang T, Zhou J, Liu S, Wang C, Zhang Y, Li H, Chen D, Lu Y. Safety evaluation of aristolactams from the edible herb Houttuynia cordata: implications for dietary exposure and food safety. Food Res Int. 2025;222(Pt 1):117663. PubMed PMID: 41267271 — the mouse study comparing aristolactams against aristolochic acid I, with the pharmacokinetic explanation for the difference.
  3. Yu X, Gao Y, Xu Y, Guo X, Guo L, Tan T, Liu F, Wan Y. Study of the Contents of Analogues of Aristolochic Acid in Houttuynia cordata by Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometry. Foods. 2022;11(3):302. PubMed PMID: 35159454 — 22 samples from 22 regions of China: no aristolochic acid I, aristolochic acid II or aristolactam I; aristolactam AII in every sample.
  4. Wu Y, Liu J, Kang S, Dai Z, Ma S. Rapid Analysis of Aristolochic Acids and Aristolactams in Houttuyniae Herba by LC-MS/MS. Molecules. 2022;27(24):8969. PubMed PMID: 36558101 — 75 batches: no aristolochic acids at a detection limit of 4 ng/mL or lower; aristolactams AII, FI and BII measured.
  5. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341(8842):387-391. PubMed PMID: 8094166 — the Belgian case series, and the origin of the whole field.
  6. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herbs. Lancet. 1994;343(8890):174. PubMed PMID: 7904018
  7. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686-1692. PubMed PMID: 10841870 — the cancer follow-up to the Belgian cohort.
  8. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A. 2007;104(29):12129-12134. PubMed PMID: 17620607 — links the Balkan disease to dietary contamination with Aristolochia clematitis.
  9. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A. 2012;109(21):8241-8246. PubMed PMID: 22493262 — mutational-signature evidence connecting exposure to upper urinary tract cancer at population scale.
  10. Aristolochic acid DNA adducts and the A-to-T mutational signature — topic search on the nitroreduction mechanism that aristolactams, lacking the nitro group, do not enter. PubMed search.
  11. Aristolactam nephrotoxicity — topic search on the compound class itself, including the cell-culture findings that run in the less reassuring direction. PubMed search.
  12. Asarum and aristolochic acid content — topic search on the within-family case that shows the hazard tracks family and genus rather than order. PubMed search.
  13. DNA barcoding for herbal product authentication — topic search covering ITS2, rbcL and psbA-trnH markers, and why a marker-compound assay cannot substitute for them. PubMed search.
  14. Adulteration and substitution in herbal supply chains — topic search on the mechanism behind every documented aristolochic acid episode. PubMed search.
  15. Chen H, Sha X, Luo Y, Chen J, Li X, Wang J, Cao G, Peng X. Acute and subacute toxicity evaluation of Houttuynia cordata ethanol extract and plasma metabolic profiling analysis in both male and female rats. J Appl Toxicol. 2021;41(12):2068-2082. PubMed PMID: 34057207 — oral rodent toxicology; note the material is an ethanolic extract, not a tea and not the injection.

External Resources

  1. IARC Monographs — the WHO cancer agency's classifications, including for aristolochic acid.
  2. LiverTox (NIH) — the reference on herb-induced liver injury, for checking whether a plant has an established hepatotoxicity record.
  3. NIDDK — Kidney Disease — the US National Institute of Diabetes and Digestive and Kidney Diseases patient information.
  4. World Flora Online — accepted names and family placement, for checking taxonomy claims like the ones on this page.

Connections


Back to Table of Contents